CL2012001290A1 - Compuestos derivados de canfenos arilados, estimulantes selectivos de receptores cb2; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad, trastorno o afeccion seleccionada de inflamacion, dolor, alergia, diabetes, ateroesclerosis, artritis y emesis, entre otras. - Google Patents

Compuestos derivados de canfenos arilados, estimulantes selectivos de receptores cb2; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad, trastorno o afeccion seleccionada de inflamacion, dolor, alergia, diabetes, ateroesclerosis, artritis y emesis, entre otras.

Info

Publication number
CL2012001290A1
CL2012001290A1 CL2012001290A CL2012001290A CL2012001290A1 CL 2012001290 A1 CL2012001290 A1 CL 2012001290A1 CL 2012001290 A CL2012001290 A CL 2012001290A CL 2012001290 A CL2012001290 A CL 2012001290A CL 2012001290 A1 CL2012001290 A1 CL 2012001290A1
Authority
CL
Chile
Prior art keywords
emesis
allergy
atherosclerosis
arthritis
diabetes
Prior art date
Application number
CL2012001290A
Other languages
English (en)
Spanish (es)
Inventor
Raphael Mechoulam
Lital Magid
Esther Shohami
Ital Bab
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43875675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001290(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of CL2012001290A1 publication Critical patent/CL2012001290A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
CL2012001290A 2009-11-19 2012-05-17 Compuestos derivados de canfenos arilados, estimulantes selectivos de receptores cb2; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad, trastorno o afeccion seleccionada de inflamacion, dolor, alergia, diabetes, ateroesclerosis, artritis y emesis, entre otras. CL2012001290A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26267709P 2009-11-19 2009-11-19

Publications (1)

Publication Number Publication Date
CL2012001290A1 true CL2012001290A1 (es) 2012-10-05

Family

ID=43875675

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001290A CL2012001290A1 (es) 2009-11-19 2012-05-17 Compuestos derivados de canfenos arilados, estimulantes selectivos de receptores cb2; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad, trastorno o afeccion seleccionada de inflamacion, dolor, alergia, diabetes, ateroesclerosis, artritis y emesis, entre otras.

Country Status (25)

Country Link
US (2) US8722938B2 (enExample)
EP (1) EP2501669B1 (enExample)
JP (1) JP5960058B2 (enExample)
KR (1) KR20120091196A (enExample)
CN (1) CN102648174B (enExample)
AU (1) AU2010320467B2 (enExample)
BR (1) BR112012010518A2 (enExample)
CA (1) CA2774868C (enExample)
CL (1) CL2012001290A1 (enExample)
CO (1) CO6481008A2 (enExample)
CR (1) CR20120247A (enExample)
EC (1) ECSP12011864A (enExample)
ES (1) ES2665519T3 (enExample)
IL (1) IL218216A (enExample)
MA (1) MA33753B1 (enExample)
MX (2) MX355972B (enExample)
MY (1) MY184647A (enExample)
NZ (1) NZ599106A (enExample)
PE (1) PE20121187A1 (enExample)
PH (1) PH12012500897A1 (enExample)
RU (1) RU2578715C2 (enExample)
SG (2) SG10201407706VA (enExample)
UA (1) UA109414C2 (enExample)
WO (1) WO2011061744A2 (enExample)
ZA (1) ZA201200752B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2578715C2 (ru) * 2009-11-19 2016-03-27 Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим, Лтд. Новые арилированные камфены, способы их получения и их применения
KR20170072876A (ko) 2014-10-27 2017-06-27 에프. 호프만-라 로슈 아게 방사성 표지된 카나비노이드 수용체 2 리간드
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US20170038184A1 (en) 2015-08-06 2017-02-09 Charles E. Ankner Formulation delivery system
MX2018004632A (es) * 2015-10-16 2018-11-09 Scythian Biosciences Inc Metodos y composiciones para el tratamiento de una lesion cerebral traumatica.
EP3538507A1 (en) 2016-11-13 2019-09-18 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Process for the preparation of hu-910 and crystalline structure thereof
RU2651754C1 (ru) * 2016-11-25 2018-04-23 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) ПРИМЕНЕНИЕ АЛИФАТИЧЕСКИХ ИМИНОПРОИЗВОДНЫХ КАМФОРЫ В КАЧЕСТВЕ ЭФФЕКТИВНЫХ ИНГИБИТОРОВ РЕПРОДУКЦИИ ВИРУСА ГРИППА штамм A/California/07/09 (H1N1) pdm09 и A/Puerto Rico/8/34 (H1N1)
KR102063962B1 (ko) * 2017-10-25 2020-01-08 대구대학교 산학협력단 캄펜을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물
EP3840854A4 (en) * 2018-08-20 2022-06-29 Bessor Pharma, LLC Novel cannabinoids and cannabinoid acids and their derivatives
US20250002435A1 (en) * 2021-10-10 2025-01-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Arylated fenchone derivatives, compositions comprising them, processes for their preparation and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE876241C (de) * 1943-04-07 1953-05-11 Lech Chemie Gersthofen Verfahren zur Herstellung von Riechstoffen aus Terpenphenolen
US2537647A (en) * 1948-02-21 1951-01-09 Firestone Tire & Rubber Co Rearrangement of terpenyl aryl ethers
DE828394C (de) * 1948-10-02 1952-01-17 Chemische Werke Huels G M B H Verfahren zur Herstellung von UEberzuegen
US2647152A (en) * 1950-07-12 1953-07-28 Firestone Tire & Rubber Co Terpenylalkylphenols and their preparation
US3284359A (en) * 1963-12-26 1966-11-08 Gen Electric Barium potassium ferrite magnetic material exhibiting non-vanishing rotational hysteresis in applied magnetic fields
GB1306217A (enExample) * 1969-07-04 1973-02-07
US3800051A (en) * 1970-09-21 1974-03-26 Dow Chemical Co Reducing serum cholesterol with certain substituted phenols
US4112000A (en) * 1974-04-11 1978-09-05 Mar-Pha, Societe D'etude Et D'exploitation De Marques Terpenophenols
GB1504862A (en) * 1974-04-11 1978-03-22 Mar Pha Etu Expl Marques Terpeno-phenoxyalkylamines
GB1548875A (en) * 1975-06-23 1979-07-18 Mar Pha Etu Expl Marques Terpnyl phen (oxy)elkyl amideines and their use in pharmaceutical compositions
US5648352A (en) 1991-09-13 1997-07-15 Merck & Co., Inc. Piperazinylcamphorsulfonyl oxytocin antagonists
HU227114B1 (en) 1999-05-11 2010-07-28 Egis Gyogyszergyar Nyilvanosan (1r, 2s, 4r)-(-)-2-[n,n-(dimethylamino-ethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane of high purity and pharmaceutically acceptable acid addition salts thereof, process for preparation of them and medicaments containing the same
UY26942A1 (es) * 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
ATE340158T1 (de) * 2000-11-08 2006-10-15 Syngenta Participations Ag Pyrrolcarboxamide und pyrrolcarbothioamide und deren agrochemische verwendungen
US8227643B2 (en) 2002-05-31 2012-07-24 Proteotech, Inc. Sirtuin 1 and the treatment of neurodegenerative diseases
US20070276034A1 (en) 2002-05-31 2007-11-29 Luke Esposito Compounds, compositions and methods for the treatment of synucleinopathies
US8455687B2 (en) 2002-05-31 2013-06-04 Proteotech, Inc. Compounds and compositions for use as modulators of tau aggregation and alleviation of tauopathies
US7601876B2 (en) 2002-05-31 2009-10-13 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis
PT1511710E (pt) * 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
RU2233262C1 (ru) * 2003-03-11 2004-07-27 Государственное учреждение Институт химии Коми научного центра Уральского отделения РАН Способ получения орто-терпенофенолов
CN1847207A (zh) * 2006-03-27 2006-10-18 上海应用技术学院 合成檀香的制备方法
RU2578715C2 (ru) * 2009-11-19 2016-03-27 Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим, Лтд. Новые арилированные камфены, способы их получения и их применения

Also Published As

Publication number Publication date
CO6481008A2 (es) 2012-07-16
AU2010320467A1 (en) 2012-04-05
ECSP12011864A (es) 2012-07-31
PH12012500897A1 (en) 2012-11-12
SG10201407706VA (en) 2015-02-27
CN102648174A (zh) 2012-08-22
US20120245366A1 (en) 2012-09-27
KR20120091196A (ko) 2012-08-17
CA2774868C (en) 2018-09-04
IL218216A (en) 2015-05-31
UA109414C2 (uk) 2015-08-25
SG179203A1 (en) 2012-04-27
MX355972B (es) 2018-05-07
EP2501669B1 (en) 2018-01-24
MX2012005634A (es) 2012-09-07
ES2665519T3 (es) 2018-04-26
RU2578715C2 (ru) 2016-03-27
US20150038728A1 (en) 2015-02-05
PE20121187A1 (es) 2012-09-23
CR20120247A (es) 2012-06-12
AU2010320467B2 (en) 2015-07-02
RU2012106897A (ru) 2013-12-27
JP5960058B2 (ja) 2016-08-02
JP2013511511A (ja) 2013-04-04
ZA201200752B (en) 2014-06-25
NZ599106A (en) 2013-07-26
MY184647A (en) 2021-04-13
EP2501669A2 (en) 2012-09-26
US8722938B2 (en) 2014-05-13
WO2011061744A2 (en) 2011-05-26
MA33753B1 (fr) 2012-11-01
IL218216A0 (en) 2012-04-30
CN102648174B (zh) 2016-04-27
BR112012010518A2 (pt) 2016-03-15
US9365534B2 (en) 2016-06-14
CA2774868A1 (en) 2011-05-26
WO2011061744A3 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
CL2008000439A1 (es) Compuestos derivados de indolina, agonistas del adrenoreceptor alfa2c, composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la congestion asociada a rinitis, sinusitis, al dolor asociado a neuropatia, inflamacion, artritis
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
CL2007003423A1 (es) Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
CL2007002607A1 (es) Compuestos derivados de aril-sulfonamida o piridin-sulfonamida; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de una enfermedad o trastorno mediado por las interacciones de los linfocitos, tales como artritis reumatoide,
CL2007002904A1 (es) Compuestos derivados de pirazolopirimidina; composicion farmaceutica; y uso para tratar una enfermedad seleccionada de diabetes, obesidad, asma y artritis entre otras.
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2007002199A1 (es) Compuestos derivados de sulfonil amida, moduladores del receptor cb2; composicion farmaceutica; y su uso para tratar enfermedades inflamatorias y autoinmune.
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2011003085A1 (es) Compuestos derivados de 1-(piperidin-4-il)-pirazol, moduladores de la actividad del receptor acoplado a proteina g, gpr 119; composicion farmaceutica; uso de los compuestos en el tratamiento de la diabetes o de una morbilidad asociada con dicha diabetes.
CL2008003655A1 (es) Anticuerpo que reconoce los restos 28-35 del peptido beta-amiloide, composicion farmaceutica que lo comprende, util para tratar una enfermedad relacionada con el peptido beta-amiloide.
GT201400111A (es) Triazolopiridinas sustituidas
ECSP088750A (es) Métodos y composiciones para antagonismo de rage
AR053720A1 (es) Forma cristalina de 1-cloro-4-((beta)-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, un metodo para su preparacion y el uso del mismo para preparar medicamentos
CL2008000403A1 (es) Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
ECSP11011294A (es) Compuestos de anillo fusionados y su uso
ECSP088874A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
CL2008002162A1 (es) Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras.